Skip to content

Using Nicotine to Reverse Age-related Auditory Processing Deficits

Using Nicotine to Reverse Age-related Auditory Processing Deficits: Human Psychophysics and Electrophysiology

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04971954
Acronym
Nicotine
Enrollment
48
Registered
2021-07-22
Start date
2022-02-01
Completion date
2026-06-30
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Auditory Perceptual Impairment, Aging

Keywords

nicotine, biomarker

Brief summary

The present study will evaluate the effects of both aging and nicotine on psychophysical tasks and electrophysiological measures. Nicotine will be administered to study participants in the form of gum that is available as an over-the-counter medication. The hypothesis is that nicotine will reverse the detrimental effects of aging on auditory processing. The proposed experiments will characterize the effects of nicotine and may eventually lead to improved treatments of hearing loss in a variety of patient populations and in healthy aging.

Detailed description

Study participants will be recruited in two age groups: young (18-28 years) and old (60-85). Each participant will participate in two psychophysical and electrophysiological test sessions. For each of the two sessions, the participant will be administered gum before the test. For one of these sessions, the gum will be polacrilex that contains 6-mg nicotine, and for the other session, the gum will be a placebo control. The study will be double-blind, meaning that neither the experimenter nor the participant will know whether the participant has received nicotine or placebo for a given session. The study has a cross-over design, meaning that all participants will receive both nicotine and placebo in separate sessions. Finally, the order of drug administration will be counterbalanced, meaning that equal numbers of participants will receive 1) nicotine in session one and placebo in session two, and 2) placebo in session one and nicotine in session two.

Interventions

OTHERNicotine gum

Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication

The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.

Sponsors

University of California, Irvine
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication. The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.

Intervention model description

The nicotine and placebo gums will be administered in randomized, double-blind, counterbalanced fashion.

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* between 18 and 85 years of age * non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking dependency * cognitive performance within two standard deviations of the CERAD mean

Exclusion criteria

* less than 18 or greater than 85 years of age * deafness or excessive hearing loss * smokers with a score between 3 and 10 on the Fagerström index of smoking dependency * history of psychiatric illness, neurological disorders, diabetes mellitus, renal failure, or cardiovascular disease * regular use of prescription medications (excluding oral contraceptives) * drug dependency

Design outcomes

Primary

MeasureTime frameDescription
Hearing thresholds1 hourHearing thresholds in dB SPL will be measured as a function of sound frequency from 125 Hz to 8000 Hz in quiet or in noise.
Modulation detection1 hourAmplitude-modulated sounds will be presented at 70 dB SPL or a comfortable level. The detection threshold in percent modulation depth (m= 0 to 100) will be recorded and converted into signal-to-noise ratios in dB (=20log(m)).
Envelope following responses2 hoursElectrophysiological responses will be recorded in response to amplitude or frequency-modulated sounds. The sounds will be presented at 70 dB SPL or a comfortable level. The EEG signal strength that is in synchrony with the modulation frequency in micro-Volts will be recorded.

Secondary

MeasureTime frameDescription
Heart rate10 minutesPulse rate in pulses per minute will be measured via pulse oximetry.
Mood change10 minutesMood change will be measured by a 9-category rating scale including: energy, contentedness, focus, relaxation, calmness, alertness, hunger etc.
Nicotine side effects10 minutesSide effects will be rated on a 5-point scale including: 1 = none (no symptoms at all); 2 = mild (slight jitters); 3 = moderate (jittery, slight dull headache); 4 = moderately severe (jittery, dull headache, mild nausea); 5 = severe (jittery, dull or pounding headache, nausea, vomiting).

Countries

United States

Contacts

CONTACTFan-Gang Zeng
fzeng@uci.edu9498249107
PRINCIPAL_INVESTIGATORFan-Gang Zeng, PhD

University of California, Irvine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026